---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-25-273416"
form_type: "8-K"
ticker: "PSNL"
cik: "0001527753"
company_name: "Personalis, Inc."
filed_at: "2025-11-10T23:59:59+00:00"
generated_at: "2026-05-16T22:21:52.614484+00:00"
event_type: "regulatory"
sentiment: "positive"
materiality_score: 0.8
calibrated_materiality_score: 0.8
confidence: "high"
source: SEC EDGAR
---

# Personalis receives Medicare coverage for NeXT Personal in breast cancer MRD surveillance

## Summary
- CMS covers NeXT Personal Dx Breast MRD test for post-treatment surveillance of stage II/III breast cancer recurrence.
- Reimbursement rate $3,878 for NeXT Personal Dx Breast MRD test; $1,158 for NeXT Personal Single Plasma Test.
- Coverage effective retroactively from October 7, 2025; Single Plasma test available up to 6 years post-treatment.
- Dx Breast MRD test covered once per cancer diagnosis; expands market access for Personalis.

## SEC filing metadata
- accession: 0001193125-25-273416
- form_type: 8-K
- ticker: PSNL
- cik: 0001527753
- company_name: Personalis, Inc.
- filed_at: 2025-11-10T23:59:59+00:00
- event_type: regulatory
- sentiment: positive
- materiality_score: 0.8
- calibrated_materiality_score: 0.8
- confidence: high
- sec_items: 8.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1527753/000119312525273416/0001193125-25-273416-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1527753/000119312525273416/d158834d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-25-273416
- JSON: https://secwatch.observer/filing/0001193125-25-273416.json
- Plain text: https://secwatch.observer/filing/0001193125-25-273416.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.